makoto tanihara ics convention design, inc
TRANSCRIPT
0
Makoto TANIHARA
ICS Convention Design, Inc.
February 2013
Asia’s Premier Partnering Event for the Biotechnology Industry
1
Event Outline
<Photo highlights 2012>
Japan Pharmaceutical Manufacturers Association
Japan Bioindustry Association
BioJapan 2013 -World Business Forum- Date: October 9 (Wed.)- 11 (Fri.), 2013
Venue: Pacifico YOKOHAMA *YOKOHAMA is a port city in Kanagawa prefecture just 30 minutes away from the center of Tokyo
Organizer: ・BioJapan Organizing Committee including,
・ICS Convention Design, Inc.
Overview
About BioJapan
BioJapan provides you an opportunity to meet with 700+
biotech and life science companies in Yokohama. Business
development teams from almost all global and Japanese
pharma companies will gather in Yokohama for the 15th
BioJapan. The 2013 event will consist of Partnering, Exhibition
and Seminars.
Synergy
Exhibition Seminars
Partnering
Overview
2
Keynote Speech
Organizer’s Seminars
Luncheon Seminars
Sponsored Seminars
BioJapan 2013 Floor Layout *Subject to change
Annex Hall Exhibition Hall *Partnering Area, Exhibition and Seminars /10,000㎡
40 Sessions in Total with
5,000+ audiences!
Exhibitor’s Presentations
Academic Seeds Presentations
100+ Sessions on
Up-to-date Seeds!
Global Partnering Seminar
Pacifico Yokohama
*Seminars
Overview
3
BioJapan 2012 highlights
Partnering:
・541 companies / 868 delegates from 22 countries
・3,372 one-to-one meetings
Exhibition:
・434 exhibitors / 351 booth stands from 18 countries
・12,369 visitors from 27 countries
Seminars:
・21 Organizer's seminars
・18 Sponsored seminars
・112 Company presentations
Overview
4
Japanese Pharma
Partnering Participating Companies at BioJapan 2012
*Almost all Japanese pharma companies participated in 2012.
Bio Cluster in Japan
*Approx. 150 Japanese biotech companies participated in 2012.
Ajinomoto, Astellas, Chugai Pharmaceutical, Daiichi-Sankyo, Dainippon Sumitomo Pharma, Eisai, Kaken Pharmaceutical, Kissei Pharmaceutical, Kyowa Hakko Kirin, Meiji Seika Pharma, Mochida Pharmaceutical, Nippon Kayaku, Nippon Shinyaku, Ono Pharmaceutical, Otsuka Pharmaceutical, Shionogi, Mitsubishi Tanabe Pharma, Takara Bio, Taisho Pharmaceutical. Takeda, Teijin Pharma, Zeria Pharmaceutical and others.
Kurume Cutting-egde Medical Research Center, Metropolitan Bio Network, Northern Advancement Center for Science & Technology, Osaka Bio Headquarter, Hokuriku Industrial Advancement Center and others.
5
6
Participating Companies at BioJapan 2012
DuPont, Fujifilm Corporation, Kaneka, Kao Corporation, Mitsubishi Chemical Corporation, Roche Diagnostics, Shiseido, Sumitomo Chemical, Teijin Group, Toray and others.
Keio University, Kyoto University, Osaka University, Tokyo Institute of Technology, Tsukuba University, University of Tokyo and others.
Partnering
AIST- National Institute of Advanced Industrial Science and Technology, JST- Japan Science and Technology Agency, Organization for Small & Medium Enterprises and Regional Innovation, RIKEN and others
Global Pharma (without Japanese pharma)
AstraZeneca, Baxter, Bristol-Myers Squibb, Eli Lilly (Japan), F. Hoffmann-La Roche, GlaxoSmithKline, Janssen Pharma, MSD, (Nippon) Boehringer Ingelheim, Novartis, Pfizer and Sanofi.
Other companies
Governmental Agencies
Academics
Online Partnering System
The BioJapan matching system is available and the
system will enable you to pre-arrange meetings prior
to the event. Create new partnerships and strengthen
existing business relationships using the system!
Partnering
<Before the event> <At the BioJapan>
The 2013 BioJapan partnering is expected to attract
700+ companies. 7
Registration fee
Your registration fee covers:
・Access to the BioJapan matching (partnering) system
・Access to the exhibition & annex hall and partnering area
・Lunch for all 3 days at the partnering area
・Wednesday Welcome Reception
・Thursday Partnering Party
Registration fee: JPY50,000 (taxes included) per person
*EUR400.00 (Based on EUR1.00=JPY125.00) or USD555.00 (Based on USD1.00=JPY90.00)
Partnering
(NEW) 14-minute presentation in the exhibition hall will be available at the extra
fee of JPY105,000 (EUR840.00 or USD1,150.00). 8
Specific Theme Zones in 2012
-Alliance zone (for Pharmaceutical Companies)
-Regenerative Medicine Zone
-Drug Development Services Zone
-In-Silico Drug Discovery Zone
General information Exhibition
Opportunity to promote your products and services to
qualified participants, especially to participants from
pharmaceutical companies!
Exhibition Categories
-Drug and Drug discovery (Small-molecule drug, biologics and vaccine etc.)
-Drug Discovery support and contract services (Drug synthesis services, Analysis contract services
and Chemical compound libraries and screening etc.)
-Medical treatment, Diagnosis and Medical devices and equipments (Biomarkers and Gene therapy etc.)
-Research Devices, Reagents and Facilities (Research Devices, Bioinformatics and Bioimaging etc.)
-Others (Functional Food, Agriculture, Bio-cluster, Universities and Government Agencies etc.)
9
Exhibition Fees and Exhibitor Benefits Exhibition
Exhibitor Benefits:
1) Partnering account(s) will be provided
according to your booth space.
2) Company name listed in the BioJapan
2013 official guidebook
3) Company Directory listing on
BioJapan 2013 website
Exhibition Fees:
・Booth space per 9 sqm:
Early bird: JPY420,000 *EUR3,360
Regular: JPY472,500 *EUR3,780
・9 sqm Shell Scheme Booth
Early bird based: JPY525,000 *EUR4,200
・4 sqm Shell Scheme Booth: JPY199,500 *EUR1,600
<Bavarian pavilion at BJ 2012>
Save EUR420 per 9sqm!
For details, see exhibitor prospects
http://www.ics-expo.jp/biojapan/images/info_exhibitor/BJ_brochure_En.pdf
10
Organizer's seminars
Seminars will consist of Keynote speech, Sponsored Seminars, Exhibitor
Presentations, Academic Seeds Presentations and Global Partnering
Seminars. The followings were the major themes of 2012 Organizer’s seminar.
The details for 2013 to be announced.
・” Medicine and Pharmaceuticals” including ”Personalized medicine“
and “ Regenerative medicine”
・” Healthcare”
・” Food and the Agriculture and Fishery Industries ”
・” Environment and Energy”
・” The Foundation of Biotechnology-based Industry”
Seminars
11
Company Presentations
BioJapan 2013 invites exhibitors to present at the conference.
<Sponsored Seminar> <Exhibitor Presentation>
Seminars
Exhibitor Presentation in the exhibition hall (Venue: A presentation venue)
・For 9 sqm or more exhibitors: JPY262,500 (EUR2,100) per 30 minutes
・For 4 aqm exhibitors: JPY105,000 (EUR840) per 30 minutes
・For Academic Laboratories and TLO: JPY42,000 (EUR336) per 30 minutes
Sponsored Seminar in the Annex hall (Venue: A private room)
・Luncheon Seminar: JPY1,260,000 (EUR10,080) per 60 minutes
・Sponsored Seminar: JPY630,000 (EUR5,040) per 60 minutes
Note: The above cost does NOT include the simultaneous interpretation service.
Note: The above cost does NOT include the simultaneous interpretation service.
12
80
90
100
110
120
06 07 08 09 10 11
YEAR(JAN-DEC)
Business Opportunities in Japan
Company *Participated in the
BioJapan 2012 partnering
Sales
Figures
Operating
profits
R&D
Spender
Takeda* 18.40 3.23 3.43
Astellas Pharma* 11.82 1.60 2.31
Daiichi Sankyo* 11.44 1.19 2.25
Otsuka pharmaceutical* 9.53 2.05 1.82
Eisai* 7.90 1.16 1.52
Mitsubishi Tanabe Pharma* 4.96 0.84 0.85
Chugai pharmaceutical* 4.55 0.76 0.68
Dainippon Sumitomo Pharma* 4.27 0.24 0.69
Kyowa Hakko Kirin* 4.19 0.56 0.54
Taisho Pharmaceutical* 3.30 0.46 0.29
Japan is currently the second-largest pharmaceuticals market in the world
with growing demand for drugs due to high life expectancy and an aging
population. Total ethical drug sales in Japan based on
NHI price levels *Unit: Billion USD
Japanese TOP 10 pharmaceutical companies
based on FY2012 sales figures *Unit: Billion USD
Continued to grow
Source: MR Biz Source: IMS Japan
*1: Total ethical drug sales 2011 in Japan based on NHI price levels were approximately 115.6 billion USD.
*Based on exchange rates: USD1.00 = JPY 82.00
*2: Total R&D spender 2012 of Japanese top 10 pharmaceutical companies were approximately 14.38 billion USD.
*Based on exchange rates: USD1.00 = JPY82.00,
*1
*2
Market
13
(Summary) Japanese Outbound M&A deals
Japanese pharmaceutical companies become more global and
strengthen their pipelines by using M&A.
Market
Company Takeover candidate Deal Value US $ Date
Takeda (Japan) LigoCyte Pharmaceuticals, Inc. (US) 492 million Nov. 2012
Takeda (Japan) URL Pharma (US) 800 million Apr. 2012
Asahi Kasei (Japan) Zoll Medical (US) 2.21 billion Mar. 2012
Dainippon Sumitomo (Japan) Boston Biomedical Inc.(US) 200 million Feb. 2012
Takeda (Japan) Intellikine (US)190 million up front plus 120 million in
contingent milestonesDec. 2011
Fujifilm (Japan) SonoSite (US) 995 million Dec. 2011
Santen Pharma (Japan) Novagali (France) 135 million (50.55% of the shares) Oct. 2011
Takeda (Japan) Nycomed (Switzerland) 3.68 billion Sep. 2011
Astellas (Japan) and Maxygen (US) Perseid Therapeutics (US) 76 million May 2011
Takeda (Japan) Fate Therapeutics (US) Undisclosed ( Unspecified stake) May 2011
Kyowa Hakko Kirin (Japan) ProStrakan (UK) 474 million Apr. 2011
Daiichi Sankyo (Japan) Plexxikon (US) 805 million Apr. 2011
Nitto Denko (Japan) Avecia Biotech (US) Undisclosed Feb. 2011
Zeria pharmaceutical (Japan) Biofac Esbjerg A/S (Denmark) 12. 3 million (85% of the shares) Sep. 2010
KANEKA (Japan) Eurogentec(Belgium) 45 million Jul. 2010
Astellas (Japan) OSI Pharmaceuticals 4.00 billion Mar. 2010
Eisai (Japan) AkaRx (US) 255 million Jan. 2010
14
(Summary) Drug Discovery Collaboration Market
Japanese pharmaceutical companies are seeking partners in
order to accelerate drug development and make more efficient
use of precious capital.
It’s said that BioJapan is the best partnering event in Japan and
provides you a great opportunity to meet pharma professionals.
Company Partner Release date
Otsuka Pharmaceutical (JPN) Living Cell Technologies Limited (Australia) Dec. 2012
Takeda (JPN) Advinu (India) Oct. 2012
Ono Pharmaceutical (JPN) Domain Therapeutics S.A. (France) Oct. 2012
Takeda (JPN) The BC Cancer Agency (Canada) Aug, 2012
Daiichi Sankyo (JPN) NGM Biopharmaceuticals, Inc. (US) Mar. 2012
Teijin Pharma (JPN) NovAliX (France) Jan. 2012
Astellas (JPN) and Agensys, Inc. (US) Seattle Genetics, Inc.(US) Jun. 2011
Eisai(JPN) UCL (UK) May 2011
Takeda (JPN) Heptares Therapeutics (UK) Apr. 2011
Takeda (JPN) Samyang Corporation (S. Korea) Apr. 2011
Daiichi Sankyo (JPN) Pieris AG (Germany) Apr. 2011
Eisai(JPN) Epizyme, Inc.(US) Mar. 2011
Astellas (JPN) Cell Signaling Technology, Inc.(US) Feb. 2011
Ono Pharmaceutical (JPN) BioFocus(UK) Jan. 2011
Eisai(JPN) FORMA Therapeutics (US) Nov. 2010
Ono Pharmaceutical (JPN) BioSeek (US) Mar. 2010
15
Japanese Biotech IPOs
・Japanese Biotech IPOs in 2011 and 2012
・The number of Japanese biotech IPOs (yearly, 2008-2012)
Market
Hit a new record high in 2011 but many biotech companies will be forced to
shut down due to lack of funding.
Company Market IPO date
Eugrena Tokyo Stock Exchange Mothers Dec. 2012
UMN Pharma Tokyo Stock Exchange Mothers Dec. 2012
GENE TECHNO SCIENCE Tokyo Stock Exchange Mothers Nov. 2012
CHIOME Biosceiece Tokyo Stock Exchange Mothers Dec. 2011
SymBio Pharmaceutical Osaka Securities Exchange JASDAQ Growth Market Oct. 2011
3D Matrix Osaka Securities Exchange JASDAQ Growth Market Oct. 2011
RaQualia Pharma Osaka Securities Exchange JASDAQ Growth Market Jul. 2011
Mebiopharm Tokyo AIM Jul. 2011
16
Thank you for your interest in BioJapan
and I look forward to seeing you all in Japan.
CONTACT
Makoto Tanihara /
Global Event Manager
ADDRESS: Chiyoda Bldg., 1-5-18 Sarugaku-cho,
Chiyoda-ku, Tokyo 101-8449 Japan
PHONE: 03-3219-3565 / FAX: 03-3219-3628
E-mail: [email protected]
Website: http://www.icsexpo.jp/biojapan/en/index.html
17